log-in
Randomisation system
log-in to secure server here

TransACT 2: Bone-marrow derived stem cell transplantation in patients undergoing left ventricular restoration surgery for dilated ischemic end-stage heart failure: a randomised-blind controlled trial

Photo courtesy of euthman

The aim of this study is to determine the effects of CD133+ autologous stem cell transplantation in and around asynergic non viable LV segments in patients with dilated ischaemic heart disease undergoing left ventricular reshaping surgery and CABG.

Study design

The study is a single centre, randomised-controlled clinical trial in patients undergoing left ventricular restoration surgery for dilated ischemic end-stage heart failure. Participants and all members of the healthcare and research team are blinded to the study allocation.

Eligible patients undergoing SVR surgery will be allocated to either:

Patients will be assigned to the intervention or control group in a 1:1 ratio using blocked randomisation.

Inclusion criteria

Participant may enter study if ALL of the following apply:

Exclusion criteria

Participant may not enter study if ANY of the following apply:

Principal investigators

Ascione R, Guttridge M, Hamilton M, Reeves BC, Angelini GD

Transact 2 logo

If you require any help, please contact:

Dr Jodi Taylor
Email: j.taylor@bristol.ac.uk
Tel: 0117 342 3398

Bristol Clinical Trials and Evaluation Unit UK Clinical Research Collaboration University of Bristol

Randomisation service provided by: Sealed Envelope™.com